12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARRY-614: Phase I data

An open-label, dose-escalation Phase I trial in 44 evaluable patients with low to intermediate-1 risk MDS showed that total daily doses of 400, 600, 900 and 1,200 mg ARRY-614 led to hematologic improvement response rates of 20% (n=15), 30% (n=10), 33% (n=3) and 38% (n=16), respectively. The MTD...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >